Biosimilars: Still Not Quite Ready for Prime Time.
Biosimilars represent a potential savings opportunity for both payers and patients, but how and when the new agents will be accepted and prescribed is uncertain.
Martha M
MM
Rumore
F
F
Randy Vogenberg
351(k) application; biologics; biosimilars; health benefits; interchangeable; pharmacy practice; substitution